{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:02:25Z","timestamp":1774314145802,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00347-018-0701-5","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T08:34:22Z","timestamp":1523349262000},"page":"476-488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Behandelte Fr\u00fchgeborenenretinopathie in\u00a0Deutschland","Treated cases of retinopathy of prematurity in Germany"],"prefix":"10.1007","volume":"115","author":[{"name":"Retina.net ROP-Register-Studiengruppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Walz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bemme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Akman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Breu\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"S\u00fcsskind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Glitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wagenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gabel-Pfisterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aisenbrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Koutsonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. U.","family":"Krohne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"issue":"8","key":"701_CR1","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1111\/aos.13069","volume":"94","author":"JM Walz","year":"2016","unstructured":"Walz JM, Bemme S, Pielen A, Aisenbrey S, Breuss H, Alex AF et\u00a0al (2016) The German ROP Registry: data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol 94(8):e744\u2013e752. \n                    https:\/\/doi.org\/10.1111\/aos.13069\n                    \n                   (Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27197876\n                    \n                  )","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"701_CR2","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1213\/ANE.0000000000000705","volume":"120","author":"HC Glass","year":"2015","unstructured":"Glass HC, Costarino AT, Stayer SA, Brett C, Cladis F, Davis PJ (2015) Outcomes for extremely premature infants. Anesth Analg 120(6):1337\u20131351","journal-title":"Anesth Analg"},{"issue":"2","key":"701_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327\u2013333","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"701_CR4","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN et\u00a0al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137(4):e20153218. \n                    https:\/\/doi.org\/10.1542\/peds.2015-3218\n                    \n                   (Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27244705\n                    \n                  )","journal-title":"Pediatrics"},{"issue":"6","key":"701_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/bjophthalmol-2016-309198","volume":"101","author":"M Karacorlu","year":"2017","unstructured":"Karacorlu M, Hocaoglu M, Muslubas IS, Arf S (2017) Long-term functional results following vitrectomy for advanced retinopathy of prematurity. Br J Ophthalmol 101(6):730\u2013734","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"701_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/MSM.897095","volume":"22","author":"SD Nicoar\u0103","year":"2016","unstructured":"Nicoar\u0103 SD, \u015etef\u0103nu\u0163 AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 22(10):1192\u20131209","journal-title":"Med Sci Monit"},{"issue":"2","key":"701_CR7","first-page":"197","volume":"109","author":"Redaktionskomitee von DOG BVA und RG","year":"2012","unstructured":"Redaktionskomitee von DOG BVA und RG (2012) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augen\u00e4rzte Deutschlands zum Einsatz von Bevacizumab in der Therapie der Fr\u00fchgeborenenretinopathie. Ophthalmologe 109(2):197\u2013204","journal-title":"Ophthalmologe"},{"issue":"2","key":"701_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-2008-1027168","volume":"225","author":"C Jandeck","year":"2008","unstructured":"Jandeck C, Kellner U, Lorenz B, Seiberth V, Arbeitsgruppe der Retinologischen Gesellschaft zur Erstellung der Leitlinie zur augen\u00e4rztlichen Screening-Untersuchung von Fr\u00fchgeborenen (2008) Guidelines for ophthalmological screening of premature infants in Germany. Klin Monbl Augenheilkd 225(2):123\u2013130","journal-title":"Klin Monbl Augenheilkd"},{"key":"701_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N et\u00a0al (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. \n                    https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr."},{"issue":"7","key":"701_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364(7):603\u2013615","journal-title":"N Engl J Med"},{"issue":"5","key":"701_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after Intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5\u2011year retrospective analysis. Ophthalmology 122(5):1008\u20131015","journal-title":"Ophthalmology"},{"issue":"3","key":"701_CR12","first-page":"365","volume":"101","author":"B Mueller","year":"2017","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C et\u00a0al (2017) Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol 101(3):365\u2013370","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"701_CR13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","volume":"58","author":"J Lyu","year":"2017","unstructured":"Lyu J, Zhang Q, Chen C\u2011L, Xu Y, Ji X\u2011D, Li J\u2011K et al (2017) Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci 58(3):1719\u20131725","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"701_CR14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/bjophthalmol-2015-307263","volume":"100","author":"G Holmstrom","year":"2016","unstructured":"Holmstrom G, Hellstrom A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A (2016) Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a\u00a0national quality register. Br J Ophthalmol 100(12):1656\u20131661. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307263\n                    \n                   (Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26969711\n                    \n                  )","journal-title":"Br J Ophthalmol"},{"key":"701_CR15","volume-title":"Bundesauswertung zum Erfassungsjahr 2015. Neonatologie. Qualit\u00e4tsindikatoren","author":"IQTIG \u2013 Institut f\u00fcr Qualti\u00e4tssicherung und Transparenz im Gesundheitswesen","year":"2016","unstructured":"IQTIG \u2013 Institut f\u00fcr Qualti\u00e4tssicherung und Transparenz im Gesundheitswesen (2016) Bundesauswertung zum Erfassungsjahr 2015. Neonatologie. Qualit\u00e4tsindikatoren. \n                    https:\/\/iqtig.org\/downloads\/ergebnisse\/qidb\/2015\/2016-05-25\/QIDB_2015_INDIREKT_PDF\/QIDB_2015_indirekte_Leistungsbereiche\/BuAw_2015_INDIREKT\/bu_Gesamt_NEO_2015.pdf\n                    \n                  . Zugegriffen: 30. Dez. 2017"},{"issue":"2","key":"701_CR16","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE (2013) Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 98(2):F170\u2013F174","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"issue":"9","key":"701_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123(9):1845\u20131855. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028\n                    \n                   (Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27241619\n                    \n                  )","journal-title":"Ophthalmology"},{"key":"701_CR18","doi-asserted-by":"publisher","first-page":"27082","DOI":"10.1038\/srep27082","volume":"6","author":"JJ Chan","year":"2016","unstructured":"Chan JJ, Lam CP, Kwok MK, Wong RL, Lee GK, Lau WW et\u00a0al (2016) Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Sci Rep 6:27082","journal-title":"Sci Rep"},{"issue":"6","key":"701_CR19","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, Roohipoor R, Ghassemi F, Imani M et al (2016) Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol 94(6):e417\u2013e420. \n                    https:\/\/doi.org\/10.1111\/aos.13008\n                    \n                   (Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27009449\n                    \n                  )","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"701_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA et\u00a0al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a\u00a0randomized clinical trial. JAMA Ophthalmol 132(11):1327\u20131333","journal-title":"JAMA Ophthalmol."},{"issue":"6","key":"701_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","volume":"128","author":"WV Good","year":"2010","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL et\u00a0al (2010) Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 128(6):663\u2013671","journal-title":"Arch Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-018-0701-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0701-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0701-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T20:16:09Z","timestamp":1554840969000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-018-0701-5"}},"subtitle":["5-Jahres-Daten des Retina.net ROP-Registers","5-year data from the Retina.net ROP registry"],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1007\/s00347-018-0701-5","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"10 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Bemme: Novartis. L.\u00a0Wagenfeld: Bayer, Novartis, Alimera Sciences, Allergan. K.\u00a0Engelmann: Novartis, Bayer. T.U.\u00a0Krohne: Alimera Sciences, Bayer, Heidelberg Engineering, Novartis. A.\u00a0Stahl: Allergan, Bayer, Boehringer Ingelheim, Novartis, Orphan Europe. J.M.\u00a0Walz, S.\u00a0Reichl, S.\u00a0Akman, H.\u00a0Breu\u00df, D.\u00a0S\u00fcsskind, B.\u00a0Glitz, V.C.\u00a0M\u00fcller, A.\u00a0Gabel-Pfisterer, S.\u00a0Aisenbrey und A.\u00a0Koutsonas geben an, dass kein Interessenkonflikt besteht. Alle angegeben Interessenskonfilkte stehen nicht in direktem Bezug zur vorgestellten Studie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Es handelt sich lediglich um eine nicht-interventionelle Auswertung erhobener klinischer Daten.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}